Product Information
EZETIMIBE 10 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.0672 per EA under NDC 00591371305. Its NADAC has been published 459 times since Oct 18, 2017.
FDA first approved this application on Jun 12, 2017.
Strength
10 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591371305
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
7/22/2026
Active Ingredients
EZETIMIBEApproval Type
Generic (ANDA)
FDA Application
ANDA200831FDA Approved
6/12/2017
On Market Since
6/12/2017
Pharmacological Classes
Price Statistics
The NADAC for EZETIMIBE 10 MG TABLET has been published 459 times since Oct 18, 2017, and over the history we have for it it has declined 84.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0672 per EA |
|---|---|
| All-time high | $0.4331 (Nov 15, 2017) |
| All-time low | $0.0672 (Jul 22, 2026) |
| 52-week high | $0.0756 |
| 52-week low | $0.0672 |
| Median price | $0.1110 |
| Average price | $0.1461 |
| Largest weekly change | +22.7% (Jun 19, 2024) |
| Weeks tracked | 459 |
| Tracking since | Oct 18, 2017 |
1W
N/A
1M
N/A
3M
-2.8%
6M
-7.3%
1Y
-5.1%
3Y
-17.0%
5Y
-53.5%
All
-84.5%
Last surveyed Jul 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ezetimibe market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EZETIMIBE 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EZETIMIBE 10 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.0672 per EA (NDC 00591371305), effective Jul 29, 2026.
How has the price of EZETIMIBE 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for EZETIMIBE 10 MG TABLET has declined 84.5%. It has been tracked across 459 weekly CMS publications since Oct 18, 2017.
What are the highest and lowest recorded NADAC prices for EZETIMIBE 10 MG TABLET?
Since Oct 18, 2017, the NADAC for EZETIMIBE 10 MG TABLET has ranged from a low of $0.0672 (Jul 22, 2026) to a high of $0.4331 (Nov 15, 2017), with a median of $0.1110 per EA.
Are there cheaper alternatives to EZETIMIBE 10 MG TABLET?
Yes. 13 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EZETIMIBE 10 MG TABLET, is $0.0667 per EA — about 1% below EZETIMIBE 10 MG TABLET.
Who manufactures EZETIMIBE 10 MG TABLET?
EZETIMIBE 10 MG TABLET (NDC 00591371305) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.